The application of the conditioning regimen of total lymphoid irradiation (TLl) and anti-thymocyte globulin (ATG) to leukemia and lymphoma patients undergoing hematopoietic cell transplantation (HCT) at the Stanford Medical Center has resulted in extension of the transplant procedure to the elderiy, and a very low incidence of acute graft versus host disease (GVHD) and transplant related mortality. However, the incidence of tumor relapse during the first 3 years after transplantation was about 50%. The patients with mixed chimerism had a relapse rate that was significantly higher than those with complete chimerism. The goals of the research program are to further study two new approaches for prevention and/or treatment of tumor relapse after HCT in mice that can be applied to clinical trials. In the first approach, we found that a subset of freshly isolated CD8+ memory T cells has potent graft anti-tumor (GVT) activity without inducing GVHD. The infusion of the latter cells into mixed chimeric mice with lymphoma relapse after transplantation resulted in conversion to complete chimerism and tumor cures after conditioning with conventional total body irradiation (TBI). We will determine whether this approach can be used in combination with the safer TLl based conditioning in mouse strain combinations that are MHC matched and mismatched, and study the molecular and cellular basis of tumor cures. We will apply the same approach in Phase l/ll clinical trials of patients with lymphoma relapse or at high risk for relapse due to mixed chimerism. In the second approach we will combine immunotherapy and allogeneic HCT for the prevention and treatment of lymphoma relapse by immunizing the donors to the idiotype protein tumor antigen. Our preliminary studies showed that the combination results in a marked increase in GVT activity. We will study the ability of infused CD8+ memory T cells from immunized donors to cure lymphoma relapse, and the molecular basis of enhanced GVT activity In both murine and human studies, recipients will be monitored for tumor burden, severity of GVHD, levels of chimerism and persistence of donor cells and CD8+ memory T cell clones.

Public Health Relevance

The development of successful new approaches to prevent or treat relapses of non-Hodgkin's lymphoma after reduced intensity conditioning for HCT would make a marked impact on long term patient survival. Currently tumor relapse is the main cause of death after transplantation, now that acute GVHD and transplant related mortality afflict less than 5% of patients including the elderly.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Sen, Nandini; Arvin, Ann M (2016) Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells. J Virol 90:3284-7
Pierini, Antonio; Alvarez, Maite; Negrin, Robert S (2016) NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int 2016:9025835
Khodadoust, M S; Luo, B; Medeiros, B C et al. (2016) Clinical activity of ponatinib in a patient with FGFR1-rearranged mixed-phenotype acute leukemia. Leukemia 30:947-50
Xu, Lian; Hunter, Zachary R; Tsakmaklis, Nicholas et al. (2016) Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia. Br J Haematol 172:735-44
Pierini, Antonio; Strober, William; Moffett, Caitlin et al. (2016) TNF-α priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood 128:866-71
Nakasone, Hideki; Sahaf, Bita; Tian, Lu et al. (2016) Presensitization to HY antigens in female donors prior to transplant is not associated with male recipient post-transplant HY antibody development nor with clinical outcomes. Haematologica 101:e30-3
Pierini, Antonio; Colonna, Lucrezia; Alvarez, Maite et al. (2015) Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. J Immunol 195:347-55
Ohgami, Robert S; Ma, Lisa; Merker, Jason D et al. (2015) Next-generation sequencing of acute myeloid leukemia identifies the significance of TP53, U2AF1, ASXL1, and TET2 mutations. Mod Pathol 28:706-14
Nakasone, Hideki; Remberger, Mats; Tian, Lu et al. (2015) Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy. Haematologica 100:1477-85
Kelley, Todd W; Arber, Daniel A; Gibson, Christine et al. (2015) Template for Reporting Results of Monitoring Tests for Patients With Chronic Myelogenous Leukemia (BCR-ABL1(+)). Arch Pathol Lab Med :

Showing the most recent 10 out of 292 publications